Abstract
Publisher Summary Immunohistological methods based on antibodies against the Ki-67 protein provided reliable and reproducible means for the determination of the growth fraction of a given human cell population, well within the scope of a routine histological laboratory. Clinical studies prove that the Ki-67 protein is an independent prognostic marker in human neoplasms, including mammary carcinoma, soft tissue sarcoma, bladder carcinoma, meningnomas, and non-Hodgkin's lymphoma. Besides the ability to characterize the growth fraction in histopathology and cancer research, the Ki-67 protein has some additional properties that fulfill the criteria for a “robust” proliferation marker. No invalid expression of the Ki-67 protein has been reported for precancerous genetic alterations in human tumors that already lead to the unscheduled expression of cell cycle regulating proteins like the cyclins. In addition, flow cytometric analysis revealed that the level of the Ki-67 protein expression is related to the different cell cycle compartments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
